MUC5AC and cystic fibrosis: P3001, a mucin-reducing agent (Ehre et al., 2019), and MUC-031, a thiol-modified carbohydrate compound (Addante et al., 2023), were tested in CF sputum and in mice with muco-obstructive lung disease (βENaC-Tg mice).